Sameer Arain, MD
Psychiatry · Saint Louis, MONPI 1750305546
Payments from drug & device makers
Across 431 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$765
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$670
- E.r. Squibb & Sons, L.L.C.$599
- Neos Therapeutics, LP$528
- Johnson & Johnson$462
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,15199%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 95 | $1,112 |
| Sunovion Pharmaceuticals Inc. | 71 | $765 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $670 |
| E.r. Squibb & Sons, L.L.C. | 48 | $599 |
| Neos Therapeutics, LP | 34 | $528 |
| Johnson & Johnson | 25 | $462 |
| Axsome Therapeutics, Inc. | 6 | $397 |
| AbbVie(2 entities) | 42 | $386 |
| Alkermes, Inc. | 9 | $307 |
| Teva Pharmaceuticals USA, Inc. | 7 | $219 |
| Vanda Pharmaceuticals Inc. | 8 | $147 |
| Neurocrine Biosciences, Inc. | 9 | $141 |
| Lundbeck LLC | 8 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $114 |
| Validus Pharmaceuticals LLC | 4 | $62 |
| Indivior Inc. | 3 | $42 |
| Bausch Health US, LLC | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Novartis | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$464
- Auvelity$345
- Austedo XR$125
- CAPLYTA$119
- SPRAVATO$108
How this compares
$6,235 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 53 | $79,498 |
| Invega SustennaPaliperidone Palmitate | 20 | $71,854 |
| Abilify MaintenaAripiprazole | 19 | $54,841 |
| FanaptIloperidone | 27 | $41,089 |
| Risperdal ConstaRisperidone Microspheres | 24 | $30,505 |
| Lurasidone Hcl | 52 | $21,163 |
| TrintellixVortioxetine Hydrobromide | 18 | $12,642 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,192 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 64 | $5,663 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 147 | $4,251 |
| Quetiapine Fumarate | 230 | $3,662 |
| Aripiprazole | 83 | $3,336 |
| Vilazodone Hcl | 15 | $3,336 |
| Chlorpromazine Hcl | 20 | $3,319 |
| Clozapine | 54 | $3,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,112 | $134,33972 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $462 | $102,35944 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $147 | $41,08927 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $114 | $20,83340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Junaid SyedSaint Louis$8M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mary KimmelSaint Louis$539K
- George GrossbergSaint Louis$521K
- Asif HabibSaint Louis$517K
- Eric LenzeSaint Louis$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.